CA1197189A - Procedures for preparing composite materials from collagen and glycosaminoglycan - Google Patents
Procedures for preparing composite materials from collagen and glycosaminoglycanInfo
- Publication number
- CA1197189A CA1197189A CA000408360A CA408360A CA1197189A CA 1197189 A CA1197189 A CA 1197189A CA 000408360 A CA000408360 A CA 000408360A CA 408360 A CA408360 A CA 408360A CA 1197189 A CA1197189 A CA 1197189A
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- glycosaminoglycan
- solution
- materials
- procedures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/122—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/08—Collagen
Abstract
PROCEDURES FOR PREPARING
COMPOSITE MATERIALS FROM
COLLAGEN AND GLYCOSAMINOGLYCAN
Abstract This invention relates to crosslinked collagen and glycosaminoglycan materials, and to procedures for preparing such materials. It has been discovered that if collagen fibrils in an aqueous acidic solution are contacted with a crosslinking agent before being contacted with glycosaminoglycan, the materials produced have extremely low levels of thrombogenicity.
Such materials are well suited for in-dwelling catheters, blood vessel grafts, and other devices that are in continuous contact with blood for long periods of time.
COMPOSITE MATERIALS FROM
COLLAGEN AND GLYCOSAMINOGLYCAN
Abstract This invention relates to crosslinked collagen and glycosaminoglycan materials, and to procedures for preparing such materials. It has been discovered that if collagen fibrils in an aqueous acidic solution are contacted with a crosslinking agent before being contacted with glycosaminoglycan, the materials produced have extremely low levels of thrombogenicity.
Such materials are well suited for in-dwelling catheters, blood vessel grafts, and other devices that are in continuous contact with blood for long periods of time.
Description
~7~L~19 1 Descrip't'ion Government Suppo:rt The invention described herein was supported in whole or in part by a grant from the National Institutes of Health.
Technica'l Field This invention is in the fields o~ polymeric materials and biocompatible materials.
' Back`ground Art Composite materials made of collagen and glycosaminoglycan (GAG) have been shown to be highly useful for certain biochemical application~. For example, U.S. Patent 4,060,081 (Yannas et al, 1977) r discloses a multilayer membrane suitable for use as synthetic skin.
The bottom layer, which is placed in contac-t ~ith'a woundbed, is a highly porous lattice comprising collagen that i5 crosslinked with GAG This lattice provides a biophysical supporting structure in which cells can migrate and proliferate to heal the wound.
The typical procedures that have been used in the past to prepare collagen/GAG composite materials are described in U.S. Patent 4,280,954 (Yannas et al, 1981).
Briefly, a preferred embodiment of those procedures com-prises the following steps, in se~uence:
.' ''~
, . ~ . .
..
Technica'l Field This invention is in the fields o~ polymeric materials and biocompatible materials.
' Back`ground Art Composite materials made of collagen and glycosaminoglycan (GAG) have been shown to be highly useful for certain biochemical application~. For example, U.S. Patent 4,060,081 (Yannas et al, 1977) r discloses a multilayer membrane suitable for use as synthetic skin.
The bottom layer, which is placed in contac-t ~ith'a woundbed, is a highly porous lattice comprising collagen that i5 crosslinked with GAG This lattice provides a biophysical supporting structure in which cells can migrate and proliferate to heal the wound.
The typical procedures that have been used in the past to prepare collagen/GAG composite materials are described in U.S. Patent 4,280,954 (Yannas et al, 1981).
Briefly, a preferred embodiment of those procedures com-prises the following steps, in se~uence:
.' ''~
, . ~ . .
..
-2- ( 1 1. Mechanically cutting and grinding a source of collagen into particulate form.
2. Soaking the particulate collagen in dilute acetic acid.
2. Soaking the particulate collagen in dilute acetic acid.
3. Homogenizing the solution in a blender.
4. Adding a source of glycosaminoglycan which has been ground into particulate form. Typically, enough GAG is added to the solution to comprise about 6~ to about 12% by dry weight of the composite material. The collagen/GAG mixture normally precipitates out of the acidic solution and forms a fibrous dispersion.
5. The precipitate is homogenized in a blender.
6. The solution is contacted with a crosslinking agent such as glutaraldehyde.
7. The solution is quickly frozen in a shallow pan.
8. The frozen dispersion is subjected to a high degree of vacuum, causing the acidic fluid to evaporate while the spatial conflguration of the partially crosslinked fibrils is maintained.
The composite material thus formed may be treated by additional procedures to remove all traces of glutaraldehyde and to increase the crosslinking density and strength of the composite mate~ial.
The resulting collagen/GAG composite material exhibits some degree of incompatibility with the blood. ~or example, a small amount of platelet aggregation may occur over a period of several months if blood is in con-tinuous contact with this material.
This degree of blood incompatibility might be tolerable if the collagen/GAG composite material is -3- ~L~
1 to be biodegraded over a relatively short period of time, as is the case when it is used as artificial skin. However, that level of blood incompatibility can lead to certain problems in the use of collagen~GAG
composite materials for prosthetic devices which are not rapidly biodegraded and which are in continous contact with blood. For example, collagen/GAG
material, in a less porous form than the lattice used for synthetic skin, may be useful for in-dwelling catheters, blood vessel replacement material, and other prosthetic devices. For such uses, it is advantageous to utili~e a composite material that does not cause platelet aggregation to any detectable extent.
. _ _4_ 1 Disclosure of the Invention This invention relates to a method of creating collagen and glycosaminoglycan (GAG) composite materials that have extremely high levels of blood compatibility. The Applicants have discovered that if an aqueous dispersion of collagen which has been swollen in acid is contacted with a crosslinking agent such as glutaraldehyde prior to adding GAG to the solution, the resulting composite material will cause extremely low or undetectable levels of blood platelet aggregation. The invention described herein also relates to composite materials formed by this method. These materials are highly useful for prosthetic devices that will remain in contact with blood for very long periods of time, including indwelling catheters, blood vessel grafts, and other prosthetic devices that are not rapidly biodegraded.
( ~5~ ~9'71~
1 sest Mode For Carrying Out This Invention In one preferred embodiment of this invention, a source of collagen is ground into pa ticulate form and contacted with dilute acetic acid. The acidic solution is stirred to ensure thorough contact of all collagen with acid~ The collagen is subsequently allowed to swell for 72 hours to remove all na~ive banding.
After swelling, a crosslinkiny agent comprising glutaraldehyde is added in the form of an aqueous solution. The final glutaraldehyde concentration is approximately equal to 0.5% weight/volume. The solution normally is stirred while the glutaraldehyde is being added.
Following the addition of glutaraldehyde, a solution of chondroitin-6-sulfate (which is a glycosaminoglycan) is added to the acidic collagen solution. The chondroitin 6-sulfate is first dissolved in dilute acetic acid, and added drop-wise to the collagen solution while it is beingstirred.
The resulting dispersion may be treated in any of several ways. In order to create a prosthetic device, it may be frozen and lyophilized. In order to test its blood compatibility propertiesl it may be filtered, air-dried, ground into particulate form, and dispersed in physiological saline solution.
7~J9 Example 1: Preparation of Collagen/GAG Material Collagen from bovine hide, prepared by the methods described by M. ~omanowsky et al, J. Amer.
Leather Chemists Assn. 69: No.9, p. 410-422 (1974), was donated b~ H. ~. Sinnamon of the V.S. Dept. of Agriculture. 0.55 g. of freeze-dried collagen was ground in a Wiley mill (A. H. Thomas Co., Phila. PA) to a 60 mesh particle si~e. It was added to 200 ml of 0.05 M aqueous acetic acid. This solution was stirred for 60 minutes in an ice-jacketed blender (Eberbach Corp., Ann Arbor, MI) on a 2-speed power unit (Waring Co., Hartford, CT) set on high speed with the line voltage reduced to 50% of 120 volts.
Following this blending step, the solution was placed in a tightly closed glass jar and the collagen was allowed to swell for 72 hours at 4C.
A solution of 25% glutaraldehyde ~'Baker-analyzed"
reagent grade, J. T. Baker Co., Phila. PA) i~
distilled water was prepared. A sufficient quantity of this solution was added to the acidic collagen - solution to comprise 0.5% glutaraldehyde yolume per volume. The glutaraldehyde solution was added while the dispersion was blended for one hour in an over-head blender (Hamilton Beach Div. of Scovill, Washington, ~.C.) set on the low speed with the line voltage reduced to 60% of 120 volts.
0.0578 g chondroitin 6-sulfate was dissolved in 10 ml of 0.05 M acetic acid. This solution was added to 175 ml of the glutaraldehyde-treated collagen dispersion. The addition was performed over a period of 5 minutes while the dispersion was being blended in the overhead blendern Shortly thereafter, the dispersion was filtered in a Buechner funnel. This filtering step was ( _7~ >7~
l completed in about 20 minutes. The resulting wet membrane was then air-dried and milled to a 60 mesh particle size. It was dispersed in physiological saline solution (0.15 M NaCl, pH7) priox to being contacted with blood platelets.
Example 2: Preparation of Collagen/GAG Control Materials Two other dispersions o~ collagen/GAG were pre-pared as described above, with the following changes.
In one specimen, the glutaraldehyde crosslinXing lO step was omitted. In the other specimen, chondroitin 6-sulfate was added to the collagen dispersion prior to the addition of glutaraldehyde.
Example 3: Blood Compatibility Testing Blood plasma that was rich in platelet content was obtained from healthy, drug-free human donors (Beth Israel Hospital, Boston, MA) by using the procedures described in F. H. Silver et al, "Glycosaminoglycan Inhibition of Collagen-Induced Platelet Aggregation," Thrombosis Research 13:
20 267-277 (1978). Platelet clotting was measured ; with an aggregometer (Chrono-Log Corporation Model 300, Broomall, PA).
When platelet-rich plasma was contacted with the collagen/GAG dispersion that had not been contacted with glutaraldehyde, the collagen/GAG
material caused rapid formation of a platelet clot. When the platelet-rich plasma was contacted with the collagen/GAG that had been contacted with glutaraldehyde subsequent to the addition of chondroitin 6-sulfate, a small amount of platelet aggregation occurred if the dispersion had been stored for a period of several months in --8~
t~
1 physiological saline prior to being contacted with platelet-rich plasma. By contrast, when the glutaraldehyde crosslinking step preceded the addition of chondroitin 6-sulfate, as described in -Example 1, no platelet aggregation could be detected, regardless of whether the dispersion was stored in physiological saline for up to one month prior to being contacted with platelet-rich plasma~
~.
_ g~
1 Industrial ~pplicability This invention has industrial applicability in the preparation of collagen prosthetic devices that have very high levels of blood compatibility.
Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.
The composite material thus formed may be treated by additional procedures to remove all traces of glutaraldehyde and to increase the crosslinking density and strength of the composite mate~ial.
The resulting collagen/GAG composite material exhibits some degree of incompatibility with the blood. ~or example, a small amount of platelet aggregation may occur over a period of several months if blood is in con-tinuous contact with this material.
This degree of blood incompatibility might be tolerable if the collagen/GAG composite material is -3- ~L~
1 to be biodegraded over a relatively short period of time, as is the case when it is used as artificial skin. However, that level of blood incompatibility can lead to certain problems in the use of collagen~GAG
composite materials for prosthetic devices which are not rapidly biodegraded and which are in continous contact with blood. For example, collagen/GAG
material, in a less porous form than the lattice used for synthetic skin, may be useful for in-dwelling catheters, blood vessel replacement material, and other prosthetic devices. For such uses, it is advantageous to utili~e a composite material that does not cause platelet aggregation to any detectable extent.
. _ _4_ 1 Disclosure of the Invention This invention relates to a method of creating collagen and glycosaminoglycan (GAG) composite materials that have extremely high levels of blood compatibility. The Applicants have discovered that if an aqueous dispersion of collagen which has been swollen in acid is contacted with a crosslinking agent such as glutaraldehyde prior to adding GAG to the solution, the resulting composite material will cause extremely low or undetectable levels of blood platelet aggregation. The invention described herein also relates to composite materials formed by this method. These materials are highly useful for prosthetic devices that will remain in contact with blood for very long periods of time, including indwelling catheters, blood vessel grafts, and other prosthetic devices that are not rapidly biodegraded.
( ~5~ ~9'71~
1 sest Mode For Carrying Out This Invention In one preferred embodiment of this invention, a source of collagen is ground into pa ticulate form and contacted with dilute acetic acid. The acidic solution is stirred to ensure thorough contact of all collagen with acid~ The collagen is subsequently allowed to swell for 72 hours to remove all na~ive banding.
After swelling, a crosslinkiny agent comprising glutaraldehyde is added in the form of an aqueous solution. The final glutaraldehyde concentration is approximately equal to 0.5% weight/volume. The solution normally is stirred while the glutaraldehyde is being added.
Following the addition of glutaraldehyde, a solution of chondroitin-6-sulfate (which is a glycosaminoglycan) is added to the acidic collagen solution. The chondroitin 6-sulfate is first dissolved in dilute acetic acid, and added drop-wise to the collagen solution while it is beingstirred.
The resulting dispersion may be treated in any of several ways. In order to create a prosthetic device, it may be frozen and lyophilized. In order to test its blood compatibility propertiesl it may be filtered, air-dried, ground into particulate form, and dispersed in physiological saline solution.
7~J9 Example 1: Preparation of Collagen/GAG Material Collagen from bovine hide, prepared by the methods described by M. ~omanowsky et al, J. Amer.
Leather Chemists Assn. 69: No.9, p. 410-422 (1974), was donated b~ H. ~. Sinnamon of the V.S. Dept. of Agriculture. 0.55 g. of freeze-dried collagen was ground in a Wiley mill (A. H. Thomas Co., Phila. PA) to a 60 mesh particle si~e. It was added to 200 ml of 0.05 M aqueous acetic acid. This solution was stirred for 60 minutes in an ice-jacketed blender (Eberbach Corp., Ann Arbor, MI) on a 2-speed power unit (Waring Co., Hartford, CT) set on high speed with the line voltage reduced to 50% of 120 volts.
Following this blending step, the solution was placed in a tightly closed glass jar and the collagen was allowed to swell for 72 hours at 4C.
A solution of 25% glutaraldehyde ~'Baker-analyzed"
reagent grade, J. T. Baker Co., Phila. PA) i~
distilled water was prepared. A sufficient quantity of this solution was added to the acidic collagen - solution to comprise 0.5% glutaraldehyde yolume per volume. The glutaraldehyde solution was added while the dispersion was blended for one hour in an over-head blender (Hamilton Beach Div. of Scovill, Washington, ~.C.) set on the low speed with the line voltage reduced to 60% of 120 volts.
0.0578 g chondroitin 6-sulfate was dissolved in 10 ml of 0.05 M acetic acid. This solution was added to 175 ml of the glutaraldehyde-treated collagen dispersion. The addition was performed over a period of 5 minutes while the dispersion was being blended in the overhead blendern Shortly thereafter, the dispersion was filtered in a Buechner funnel. This filtering step was ( _7~ >7~
l completed in about 20 minutes. The resulting wet membrane was then air-dried and milled to a 60 mesh particle size. It was dispersed in physiological saline solution (0.15 M NaCl, pH7) priox to being contacted with blood platelets.
Example 2: Preparation of Collagen/GAG Control Materials Two other dispersions o~ collagen/GAG were pre-pared as described above, with the following changes.
In one specimen, the glutaraldehyde crosslinXing lO step was omitted. In the other specimen, chondroitin 6-sulfate was added to the collagen dispersion prior to the addition of glutaraldehyde.
Example 3: Blood Compatibility Testing Blood plasma that was rich in platelet content was obtained from healthy, drug-free human donors (Beth Israel Hospital, Boston, MA) by using the procedures described in F. H. Silver et al, "Glycosaminoglycan Inhibition of Collagen-Induced Platelet Aggregation," Thrombosis Research 13:
20 267-277 (1978). Platelet clotting was measured ; with an aggregometer (Chrono-Log Corporation Model 300, Broomall, PA).
When platelet-rich plasma was contacted with the collagen/GAG dispersion that had not been contacted with glutaraldehyde, the collagen/GAG
material caused rapid formation of a platelet clot. When the platelet-rich plasma was contacted with the collagen/GAG that had been contacted with glutaraldehyde subsequent to the addition of chondroitin 6-sulfate, a small amount of platelet aggregation occurred if the dispersion had been stored for a period of several months in --8~
t~
1 physiological saline prior to being contacted with platelet-rich plasma. By contrast, when the glutaraldehyde crosslinking step preceded the addition of chondroitin 6-sulfate, as described in -Example 1, no platelet aggregation could be detected, regardless of whether the dispersion was stored in physiological saline for up to one month prior to being contacted with platelet-rich plasma~
~.
_ g~
1 Industrial ~pplicability This invention has industrial applicability in the preparation of collagen prosthetic devices that have very high levels of blood compatibility.
Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.
Claims (6)
1. A method for preparing a crosslinked collagen-glycosaminoglycan composite material, comprising:
a. soaking collagen in an aqueous acidic solution having a pH of below about six;
b. contacting said solution with a cross-linking agent; and c. contacting a source of glycosaminoglycan with said solution.
a. soaking collagen in an aqueous acidic solution having a pH of below about six;
b. contacting said solution with a cross-linking agent; and c. contacting a source of glycosaminoglycan with said solution.
2. In the method of preparing crosslinked collagen-glycosaminoglycan composite material, the improvement of contacting collagen, which has been soaked in an aqueous acidic solution, with a crosslinking agent prior to contacting said collagen and said crosslinking agent with glycosaminoglycan.
3. A method of Claims 1 or 2 wherein said aqueous acidic solution comprises acetic acid.
4. A method of Claims 1 or 2 wherein said crosslinking agent comprises glutaraldehyde.
5. A method of Claims 1 or 2 wherein said glycosaminoglycan is selected from the following group: chondroitin 6-sulfate, chondroitin 4-sulfate, heparin, heparin sulfate, keratan sulfate, dermatan sulfate, or chitin.
6. A crosslinked collagen-lycosaminoglycan composite material made by the methods of Claims 1 or 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/287,998 US4350629A (en) | 1981-07-29 | 1981-07-29 | Procedures for preparing composite materials from collagen and glycosaminoglycan |
US287,998 | 1981-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1197189A true CA1197189A (en) | 1985-11-26 |
Family
ID=23105318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000408360A Expired CA1197189A (en) | 1981-07-29 | 1982-07-29 | Procedures for preparing composite materials from collagen and glycosaminoglycan |
Country Status (2)
Country | Link |
---|---|
US (1) | US4350629A (en) |
CA (1) | CA1197189A (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2517315B1 (en) * | 1981-11-30 | 1985-12-20 | Tech Cuir Centre | PROCESS FOR THE PREPARATION OF NEW FORMS OF COLLAGEN, NATIVE OR DERETICULATED, WITH PRESERVED HELICOIDAL STRUCTURE, ASSOCIATED WITH MUCOPOLYSACCHARIDES AND THEIR APPLICATIONS IN PARTICULAR IN THE COSMETOLOGICAL, PHARMACEUTICAL, ANALYTICAL AND OTHER FIELDS |
EP0121008A3 (en) * | 1983-03-29 | 1985-03-27 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
US4448718A (en) * | 1983-09-13 | 1984-05-15 | Massachusetts Institute Of Technology | Method for the preparation of collagen-glycosaminoglycan composite materials |
US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
US4585754A (en) * | 1984-01-09 | 1986-04-29 | Valcor Scientific, Ltd. | Stabilization of proteins and peptides by chemical binding with chondroitin |
US4745098A (en) * | 1984-02-24 | 1988-05-17 | The Regents Of The University Of California | Compositions and method for improving wound healing |
US4808570A (en) * | 1984-02-24 | 1989-02-28 | University Of California | Compositions and method for improving wound healing |
US4837285A (en) * | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
CA1295796C (en) * | 1984-03-27 | 1992-02-18 | Conrad Whyne | Biodegradable matrix and methods for producing same |
US5629191A (en) * | 1985-01-03 | 1997-05-13 | Integra Lifesciences Corporation | Method of making a porous matrix particle |
JPS61253065A (en) * | 1985-05-02 | 1986-11-10 | 片倉チツカリン株式会社 | Medical composite material of chitosan derivative and collagen and its production |
FR2585576B1 (en) * | 1985-07-30 | 1992-01-03 | Bioetica Sa | BONE MATRIX REPLACEMENT PROMOTING OSTEOGENESIS |
DE3778195D1 (en) * | 1986-04-07 | 1992-05-21 | Agency Ind Science Techn | ANTITHROMOGENIC MATERIAL. |
US4760131A (en) * | 1986-04-23 | 1988-07-26 | Collagen Corporation | Wound-healing composition |
CA1294546C (en) * | 1986-04-23 | 1992-01-21 | John S. Sundsmo | Wound healing composition containing collagen |
US4751935A (en) * | 1987-04-09 | 1988-06-21 | Lee Pharmaceuticals | Artificial fingernail |
US5273900A (en) * | 1987-04-28 | 1993-12-28 | The Regents Of The University Of California | Method and apparatus for preparing composite skin replacement |
US5116374A (en) * | 1989-03-02 | 1992-05-26 | Regen Corporation | Prosthetic meniscus |
US4880429A (en) * | 1987-07-20 | 1989-11-14 | Stone Kevin R | Prosthetic meniscus |
US5108438A (en) * | 1989-03-02 | 1992-04-28 | Regen Corporation | Prosthetic intervertebral disc |
US5158574A (en) * | 1987-07-20 | 1992-10-27 | Regen Corporation | Prosthetic meniscus |
US5258043A (en) * | 1987-07-20 | 1993-11-02 | Regen Corporation | Method for making a prosthetic intervertebral disc |
US5735902A (en) * | 1987-07-20 | 1998-04-07 | Regen Biologics, Inc. | Hand implant device |
US5263984A (en) * | 1987-07-20 | 1993-11-23 | Regen Biologics, Inc. | Prosthetic ligaments |
US5681353A (en) * | 1987-07-20 | 1997-10-28 | Regen Biologics, Inc. | Meniscal augmentation device |
US5007934A (en) * | 1987-07-20 | 1991-04-16 | Regen Corporation | Prosthetic meniscus |
US5306311A (en) * | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US4947840A (en) * | 1987-08-21 | 1990-08-14 | Massachusetts Institute Of Technology | Biodegradable templates for the regeneration of tissues |
US4955893A (en) * | 1988-05-09 | 1990-09-11 | Massachusetts Institute Of Technologh | Prosthesis for promotion of nerve regeneration |
US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
FR2652741B1 (en) * | 1989-10-10 | 1994-03-04 | Laboratoires Care System | ANTIMICROBIAL COMPOSITION FOR APPLICATION TO THE SKIN, APPLICATIONS AS A BODY DEODORANT AND CUTANEOUS BACTERICIDE. |
US5282859A (en) * | 1990-04-24 | 1994-02-01 | Mark Eisenberg | Composite living skin equivalents |
US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
US5209776A (en) * | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US8067149B2 (en) * | 1990-09-12 | 2011-11-29 | Lifecell Corporation | Acellular dermal matrix and method of use thereof for grafting |
US5705178A (en) * | 1991-05-31 | 1998-01-06 | Gliatech, Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
DE4200080A1 (en) * | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmaceutical composition for wound, scar and keloid treatment |
US5916557A (en) * | 1993-11-12 | 1999-06-29 | The Trustees Of Columbia University In The City Of New York | Methods of repairing connective tissues |
US5714582A (en) * | 1995-03-17 | 1998-02-03 | Bioscience Consultants | Invertebrate type V telopeptide collagen, methods of making, and use thereof |
US6337389B1 (en) * | 1995-03-17 | 2002-01-08 | Bioscience Consultants, L.L.C. | Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof |
US5814328A (en) * | 1997-01-13 | 1998-09-29 | Gunasekaran; Subramanian | Preparation of collagen using papain and a reducing agent |
FI974321A0 (en) * | 1997-11-25 | 1997-11-25 | Jenny Ja Antti Wihurin Rahasto | Multiple heparinglycosaminoglycans and proteoglycans are used |
US6933326B1 (en) | 1998-06-19 | 2005-08-23 | Lifecell Coporation | Particulate acellular tissue matrix |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
DE19908318A1 (en) * | 1999-02-26 | 2000-08-31 | Michael Hoffmann | Hemocompatible surfaces and methods of making them |
US6964685B2 (en) * | 1999-06-22 | 2005-11-15 | The Brigham And Women's Hospital, Inc. | Biologic replacement for fibrin clot |
WO2003092468A2 (en) * | 2002-04-29 | 2003-11-13 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
US7309359B2 (en) * | 2003-08-21 | 2007-12-18 | Warsaw Orthopedic, Inc. | Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs |
US20040054414A1 (en) * | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
CN1697634A (en) * | 2002-09-18 | 2005-11-16 | Sdgi控股股份有限公司 | Natural tissue devices and methods of implantation |
CN100394989C (en) * | 2002-11-15 | 2008-06-18 | 华沙整形外科股份有限公司 | Collagen-based materials and methods for augmenting intervertebral discs |
US8138265B2 (en) * | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US6982298B2 (en) * | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US7465766B2 (en) * | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8137688B2 (en) * | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8465537B2 (en) * | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
EP1660013A4 (en) | 2003-08-26 | 2011-07-20 | Gel Del Technologies Inc | Protein biomaterials and biocoacervates and methods of making and using thereof |
US20070190101A1 (en) * | 2004-03-31 | 2007-08-16 | Chunlin Yang | Flowable bone grafts |
WO2005115259A2 (en) * | 2004-05-24 | 2005-12-08 | Biomedical Strategies | Wound closure system and methods |
GB2424223C (en) * | 2005-03-07 | 2011-02-02 | Massachusetts Inst Technology | Biomaterial. |
EP1926459B1 (en) * | 2005-09-19 | 2015-01-07 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US8118779B2 (en) | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
US8399619B2 (en) | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
PT2097116E (en) | 2006-12-22 | 2012-12-06 | Medidom Lab | In situ system for intra-articular chondral and osseous tissue repair |
US20090054984A1 (en) * | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
US8070827B2 (en) * | 2007-07-03 | 2011-12-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
EP2182887B1 (en) * | 2007-08-20 | 2016-12-14 | Histogenics Corporation | A method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
AU2008345047A1 (en) | 2007-12-26 | 2009-07-09 | Gel-Del Technologies, Inc. | Biocompatible protein particles, particle devices and methods thereof |
ES2585483T3 (en) | 2008-02-13 | 2016-10-06 | The Cleveland Clinic Foundation | Molecular improvement of the extracellular matrix and methods of use |
EP2300042A4 (en) * | 2008-04-30 | 2012-05-02 | Cleveland Clinic Foundation | Compositions and methods to treat urinary incontinence |
US8771170B2 (en) * | 2008-08-01 | 2014-07-08 | Microaccess, Inc. | Methods and apparatus for transesophageal microaccess surgery |
WO2010057177A2 (en) | 2008-11-17 | 2010-05-20 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
WO2013096249A1 (en) | 2011-12-20 | 2013-06-27 | Lifecell Corporation | Sheet tissue products |
ES2726105T3 (en) | 2011-12-20 | 2019-10-01 | Lifecell Corp | Fluidizable fabric products |
US9271821B2 (en) | 2012-01-24 | 2016-03-01 | Lifecell Corporation | Elongated tissue matrices |
EP2841115B1 (en) | 2012-04-24 | 2019-07-10 | LifeCell Corporation | Functionalized tissue matrices |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3527225A (en) * | 1964-09-29 | 1970-09-08 | David F Smith | Resorbable surgical sutures from fibrous proteins |
US4060081A (en) * | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4280954A (en) * | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
-
1981
- 1981-07-29 US US06/287,998 patent/US4350629A/en not_active Expired - Lifetime
-
1982
- 1982-07-29 CA CA000408360A patent/CA1197189A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
US4350629A (en) | 1982-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1197189A (en) | Procedures for preparing composite materials from collagen and glycosaminoglycan | |
CA1087610A (en) | Crosslinked collagen mucopolysaccharide composite materials | |
US4280954A (en) | Crosslinked collagen-mucopolysaccharide composite materials | |
Baier | The role of surface energy in thrombogenesis. | |
Tang et al. | Fibrin (ogen) mediates acute inflammatory responses to biomaterials. | |
US5037377A (en) | Means for improving biocompatibility of implants, particularly of vascular grafts | |
EP0200574B1 (en) | A biomaterial comprising a composite material of chitosan derivative and collagen and a process for the production of the same | |
US5415619A (en) | Method of manufacturing a vascular graft impregnated with polysaccharide derivatives | |
Rao et al. | Use of chitosan as a biomaterial: studies on its safety and hemostatic potential | |
Wachol-Drewek et al. | Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin | |
US4776890A (en) | Preparation of collagen hydroxyapatite matrix for bone repair | |
US5709934A (en) | Bipolymer foams having extracellular matrix particulates | |
US5298255A (en) | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material | |
Brash et al. | Protein adsorption studies on'standard'polymeric materials | |
US20040248774A1 (en) | Injectable implant of insoluble globin | |
Woerly et al. | Intracerebral implantation of synthetic polymer/biopolymer matrix: a new perspective for brain repair | |
EP0366564B1 (en) | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material | |
Chia-Lai et al. | Sugar-based collagen membrane cross-linking increases barrier capacity of membranes | |
Dickinson et al. | Biodegradation of a poly (α‐amino acid) hydrogel. I. In vivo | |
Ben Slimane et al. | Characteristics of polyester arterial grafts coated with albumin: the role and importance of the cross-linking chemicals | |
Kinoshita et al. | Soft tissue reaction to collagen-immobilized porous polyethylene: subcutaneous implantation in rats for 20 wk | |
Sharma | Blood-compatible materials: a perspective | |
Lohrr et al. | Evaluation of two epoxy ether compounds for biocompatible potential | |
Spanel-Borowski | The chick chorioallantoic membrane as test system for biocompatible materials | |
Merhi et al. | Cellular reactions to polyester arterial prostheses impregnated with cross-linked albumin: in vivo studies in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |